Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma

References

• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011:498–505.
   Google Scholar
• Armitage JO. Who benefits from surveillance imaging? J Clin Oncol 2012;30:2579–2580.
   PubMed Web of Science ®Google Scholar
• Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 2007;21:841–854.
   PubMed Web of Science ®Google Scholar
• Tilly H, Vitolo U, Walewski J, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl. 7):vii78–vii82.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Abramson SD, Advani RH, et al. The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. Version 1.2013. 2013. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
   Google Scholar
• Armitage JO. My treatment approach to patients with diffuse large B-cell lymphoma. Mayo Clin Proc 2012;87:161–171.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, et al. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 2006;24:146–150.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Wagner-Johnston ND, Bartlett NL. Role of routine imaging in lymphoma. J Natl Compr Canc Netw 2011;9:575–584.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009;50:1257–1260.
   PubMed Web of Science ®Google Scholar
• Griner PF, Mayewski RJ, Mushlin AI, Greenland P. Selection and interpretation of diagnostic tests and procedures. Principles and applications. Ann Intern Med 1981;94:557–592.
   PubMed Web of Science ®Google Scholar
• Radford JA, Eardley A, Woodman C, et al. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ 1997;314:343–346.
   PubMed Web of Science ®Google Scholar
• Guppy AE, Tebbutt NC, Norman A, et al. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:123–125.
   PubMed Web of Science ®Google Scholar
• Liedtke M, Hamlin PA, Moskowitz CH, et al. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006;17:909–913.
   PubMed Web of Science ®Google Scholar
• Kony SJ, de Vathaire F, Chompret A, et al. Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet 1997;350:91–95.
   PubMed Web of Science ®Google Scholar
• Guadagnolo BA, Punglia RS, Kuntz KM, et al. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol 2006;24:4116–4122.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Charlson ME, Schenkein E, et al. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol 2010;21:2262–2266.
   PubMed Web of Science ®Google Scholar
• Elis A, Blickstein D, Klein O, et al. Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies. Am J Hematol 2002;69:41–44.
   PubMed Web of Science ®Google Scholar
• Weeks JC, Yeap BY, Canellos GP, et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991;9:1196–1203.
   PubMed Web of Science ®Google Scholar
• Avivi I, Zilberlicht A, Dann EJ, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol 2013;88:400–405.
   PubMed Web of Science ®Google Scholar
• El-Galaly T, Prakash V, Christiansen I, et al. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leuk Lymphoma 2011;52:597–603.
   PubMed Web of Science ®Google Scholar
• Abel GA, Vanderplas A, Rodriguez MA, et al. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma 2012;53:1113–1116.
   PubMed Web of Science ®Google Scholar
• Goldschmidt N, Or O, Klein M, et al. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol 2011;90:165–171.
   PubMed Web of Science ®Google Scholar
• Petrausch U, Samaras P, Haile SR, et al. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol 2010;21:1694–1698.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781–1787.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Hofman MS, Dickinson M, et al. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 2013;109:312–317.
   PubMed Web of Science ®Google Scholar
• Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl. 4):110–112.
   PubMed Web of Science ®Google Scholar